Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2025 financial results and provide a Company update after the ...

AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of ...

"The strong global launch of YORVIPATH positions 2025 to be an inflection point for Ascendis with growing revenue and a path ...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2025 Healthcare Conference. Company management ...

Entos Pharmaceuticals (Entos), a clinical-stage genetic medicines company headquartered in Edmonton, Canada, with offices in London, UK, and San Diego, USA, will be participating in the 2025 Bloom ...

Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today ...

The Cambridge, England-based pharmaceutical company said its Kalos and Logos phase 3 trials showed Breztri achieved statistically significant and clinically meaningful improvements in lung function ...

Musk’s arrival at the social platform has raised questions for users, which includes pharma companies who use Twitter ... after an account using its name and logo sent out a Tweet, which read ...

New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent MELBOURNE, Australia, April 29, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] ...

The logo represented product uniformity ... of two strengths that has propelled BMS into the top 20 list of pharmaceutical companies of the world. By 1995, the company had over 60 product lines ...

We recently published a list of the 15 Best Growth Stocks to Buy for the Next 3 Years. In this article, we are going to take ...